Advice on using over-the-counter nicotine replacement therapy-patch, gum, or lozenge-to quit smoking

Kozlowski, Lynn T.; Giovino, Gary A.; Edwards, Beth; DiFranza, Joseph R.; Foulds, Jonathan; Hurt, R. Douglas; Niaura, Raymond; Sachs, David P.L.; Selby, Peter; Dollar, Katherine M.; Bowen, Deborah J.; Cummings, K. Michael; Counts, Mona M.; Fox, Brion J.; Sweanor, David; Ahern, Frank M.

doi:10.1016/j.addbeh.2007.01.030

Cited by 40 publications

(30 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 1995 approval of nicotine gum for over-thecounter marketing provides a detailed benefit-risk assessment based on a decade of marketing experience and further studies, as well as the postmarketing surveillance and other risk-management program commitments of the sponsor (FDA, 1995). Despite decades of experience, the labeling and warnings have changed relatively little, despite efforts by leading organizations and experts in support of extensions of the use and inclusion of instructions that are predicted to help more people quit smoking (eg, combination use of products such as nicotine gum and nicotine patch, the use of products to reduce rather than cease smoking, and initiation of medication use before smoking cessation to facilitate cessation) (Carpenter et al, 2013;Fiore et al, 2008;Fucito et al, 2014;Kozlowski et al, 2007). (By way of disclosure and basis for his insights, JEH provided consulting services to GlaxoSmithKline, which was also exploring such extensions of the indication.)…”

Section: Opioid and Nicotine Agonist Therapiesmentioning

confidence: 99%

Agonist Medications for the Treatment of Cocaine Use Disorder

Negus

Henningfield

2014

Neuropsychopharmacol

View full text Add to dashboard Cite

Section: Opioid and Nicotine Agonist Therapiesmentioning

confidence: 99%

Agonist Medications for the Treatment of Cocaine Use Disorder

Negus

Henningfield

2014

Neuropsychopharmacol

View full text Add to dashboard Cite

“…There are several safe and effective means to support quit attempts in the general population such as behavioral counselling (Barth et al, 2006;Vidrine, et al, 2006), nicotine replacement therapy (NRT) (Fiore, 2000;Hurt, 1999;Kozlowski et al, 2007) and psychoactive medication (Aubin et al, 2004;Bolin, Lindgren, and Willers, 2006;Boshier, Wilton, and Shakir, 2003;Mansourati et al, 2005;Tonnesen et al, 2003;Tonstad and Johnston, 2004;Wilkes et al, 2005;Wu et al, 2006). Within cardiac samples, psychoactive medications may have the benefit of addressing both the hazardous burden of depression and smoking.…”

Section: Antidepressant Use Among Cardiac Patientsmentioning

confidence: 99%

The association among depressive symptoms, smoking status and antidepressant use in cardiac outpatients

et al. 2009

View full text Add to dashboard Cite

Both depression and smoking are highly prevalent and related to poorer outcomes in cardiac patients. In this study, the authors examined the association between depressive symptoms and smoking status, described the frequency and type of antidepressant use, and prospectively tested the effects of antidepressant use in smokers on smoking status and psychosocial outcomes. Participants comprised 1498 coronary artery disease (CAD) outpatients who completed a baseline survey which assessed depressive symptoms, current medications, and smoking status. A second survey was mailed 9 months later that assessed depressive symptoms, anxiety, insomnia, current medications and smoking status. Results showed that current and former-smokers had significantly greater depressive symptoms than non-smokers. Ten percent of patients were taking antidepressants, most frequently SSRIs, with significantly more smokers on antidepressants than former and non-smokers. At follow-up, smokers on antidepressants were less likely to have quit, had greater anxiety, depressive symptoms and insomnia than smokers not using antidepressants. This study demonstrated that smokers and quitters with CAD had greater depressive symptoms and use of antidepressants than non-smokers, but that the antidepressants utilized may not be optimizing outcomes.

show abstract

“…However, even insured smokers may bear a significant portion of the cost of pharmacotherapy because of deductibles and copayments or, in some cases, because of noncoverage. 76,80 In some cases, coverage is extended only to certain groups of smokers. For example, Medicare covers smoking-cessation counseling and pharmacotherapy (excluding over-the-counter treatment) for seniors with tobacco-related illnesses, and in some states, the Medicaid program covers treatments only for pregnant women.…”

Section: Smoke-free Initiatives To Reduce Exposure To Secondhand Smokementioning

confidence: 99%

Tobacco Control in the United States--Recent Progress And Opportunities

Cokkinides

Bandi

McMahon

et al. 2009

CA: A Cancer Journal for Clinicians

111

View full text Add to dashboard Cite

Effective tobacco control efforts have resulted in substantial declines in tobacco use and tobacco-related cancer deaths in the United States. Nearly 40% of reductions in male lung cancer deaths between 1991 and 2003 can be attributed to smoking declines in the last half century. Nevertheless, tobacco use still remains the single, largest preventable cause of disease and premature death in the United States. Each year, smoking and exposure to secondhand smoke result in nearly half a million premature deaths of which nearly one-third are due to cancer. In a previous report, we described youth and adult smoking prevalence and patterns and discussed policy measures that had proven effective in comprehensive tobacco control. In this report, we update trends in youth and adult smoking prevalence. We find that while adult smoking prevalence has declined overall, socioeconomic gradients in smoking still persist within race and ethnic subgroups. In addition, we describe the diffusion of tobacco-control strategies at the national, state, and community level. Although recent developments, such as the Food and Drug Administration's (FDA) regulation of tobacco products, hold promise for tobacco control, there continues to be a need for broader dissemination of sustainably funded comprehensive national and state tobacco-control programs.

show abstract

Advice on using over-the-counter nicotine replacement therapy-patch, gum, or lozenge-to quit smoking

Cited by 40 publications

References 27 publications

Agonist Medications for the Treatment of Cocaine Use Disorder

Agonist Medications for the Treatment of Cocaine Use Disorder

The association among depressive symptoms, smoking status and antidepressant use in cardiac outpatients

Tobacco Control in the United States--Recent Progress And Opportunities

Contact Info

Product

Resources

About